Please login to the form below

Not currently logged in
Email:
Password:

VTE

This page shows the latest VTE news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s upadacitinib aces phase III trial

AbbVie’s upadacitinib aces phase III trial

Crucially for AbbvVie, there were no cases of venous thromboembolism (VTE) in the 1, 629-patent study, something that was observed in two earlier phase III studies of the drug ... Analysts said the lack of VTEs in the latest study reduced the risk in the

Latest news

More from news
Approximately 4 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    It is indicated for the prevention of VTE after orthopaedic surgery and is administered subcutaneously once daily. ... The drug is also in phase III development for the acute treatment of VTE.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • FCB Halesway

    Eczema. BMS. Metastatic melanoma. Lung cancer. Boehringer Ingelheim. VTE prophylaxis. DVT/PE.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics